Drug Review: Oteseconazole

International Journal of Pharmacology and Clinical Sciences, 2023, 12, 4, 187–188.
Published: February 2024
Type: Research Article
Authors: Juman Alsaab
Author(s) affiliations:

Juman Alsaab,

Pharm D, Ministry of Health, Riyadh, SAUDI ARABIA.



Registrations: It had been registered in the following countries: United Kingdom (U.K.), United States of America (USA), Canada, and Saudi Arabia (SA). Trade name (USA.); VIVJOA ® Registration number (S.A.): Not available Insurance Drug Formulary (S.A.): Not available General Information: Registered Company: Mycovia Pharmaceuticals, Inc. Regulatory Status: R.X. Mechanism of Action: Inhibitor targeting the fungal sterol by inhibition of CYP51 results accumulation of 14-methylated sterols, which are toxic to fungi. Read more…